Clinical Trial

A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability, and pharmacokinetics of DT-216P2 administered multiple ascending doses in patients with FA.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-03-11.
Status change: Not Yet Recruiting → Recruiting 2025-05-14
Trial Details
NCT Number NCT06874010
Lead Sponsor Design Therapeutics, Inc.
Conditions Friedreich Ataxia
Enrollment 20 participants
Start Date 2025-06
Primary Completion 2026-12 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-05-18